Results 11 to 20 of about 4,535 (170)

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Clinical Case Reports (discontinued), 2023
Key Clinical Message Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on ...
Sarya Swed
exaly   +2 more sources

Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study. [PDF]

PLoS ONE
BackgroundAdministration of Paxlovid in early stage has been proved to reduce the risk of hospitalization or death by 89% in mild to moderate COVID-19 patients with high-risk. There were few evidences of Paxlovid in severe COVID-19 patients.
Yu-Ji Wang, Nan Su, Jun-Hong Jiang, Guo-Peng Xu, Ran Wang, Da-Xiong Zeng, Jiao Zhu   +6 more
doaj   +2 more sources

Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia. [PDF]

PLoS Medicine
BackgroundPreventing and treating post-acute sequelae of COVID-19 infection (PASC), commonly known as Long COVID, has become a public health priority. This study tests whether Paxlovid treatment in the acute phase of COVID-19 could help prevent the onset
Alexander Preiss, Abhishek Bhatia, Leyna V Aragon, John M Baratta, Monika Baskaran, Frank Blancero, Michael Daniel Brannock, Robert F Chew, Iván Díaz, Megan Fitzgerald, Elizabeth P Kelly, Andrea G Zhou, Thomas W Carton, Christopher G Chute, Melissa Haendel, Richard Moffitt, Emily Pfaff, N3C Consortium and the RECOVER Cohort   +17 more
doaj   +2 more sources

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]

Scientific Reports
Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia, Junyi Sun, Di Zhu, Ling Wang, Xiaobo Hu, Haiyu Wang, Guowu Qian, Donghua Zhang, Silin Li, Hong Luo, Shixi Zhang, Guotao Li, Guangming Li, Hongxia Liang, Zujiang Yu, Zhigang Ren   +15 more
doaj   +2 more sources

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]

BMJ Open
Objectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang, Zhigang Ren, Xiaoli Jin, Hong Luo, Donghua Zhang, Ming Cheng, Fuwei Wang, Bohan Jia, Guotao Li, Mengzhao Yang, Guangming Li, Shixi Zhang, Guowu Qian, Silin Li, Hongxia Liang   +14 more
doaj   +2 more sources

Paxlovid utilization and social vulnerability: trends in Connecticut from 2022 to 2023 [PDF]

Antimicrobial Stewardship & Healthcare Epidemiology
The COVID-19 pandemic disproportionately affected vulnerable communities. Social vulnerability index (SVI) for census tracts with a Paxlovid dispensing site was higher than those without a dispensing site (0.56 vs. 0.45, P < .01).
Laura Hohenstein, Meghan Maloney, David B. Banach   +2 more
doaj   +2 more sources

Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. [PDF]

Immun Inflamm Dis
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Kuo HT, Hsu AY, Liu DY, Wu BQ, Wei JC, Hsia NY, Shao YC, Lai CT, Chiang CC, Lin CJ, Chen HS, Wang YH, Tseng H, Hsu HC, Tsai YY.   +14 more
europepmc   +2 more sources

Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic

Journal of Infection and Public Health, 2023
Background: Paxlovid is an oral drug composed of nirmatrelvir and ritonavir that has been demonstrated to be effective in decreasing the risk of severe coronavirus disease 2019 (COVID-19).
Chih-Wei Lin, Yu-Ling Liang, Ming-Ta Chuang, Chun-Han Tseng, Pei-Yin Tsai, Mei-Tsz Su   +5 more
doaj   +1 more source

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2 [PDF]

Osong Public Health and Research Perspectives, 2022
Objectives On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19). Methods From February 6,
Hanul Park, Young Joon Park, Hye Young Lee, Mi Yu, Yeong-Jun Song, Sang Eun Lee, Ji-Joo Lee, Eun-Sol Lee, Yeonjung Kim   +8 more
doaj   +1 more source

Ranolazine Toxicity Secondary to Paxlovid

Cureus, 2023
An Emergency Use Authorization (EUA) was issued by the FDA on December 22, 2021 for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (Paxlovid - Pfizer) for outpatient treatment of mild to moderate COVID-19 in children 12 years and old that are high risk of severe disease.
Casey, Bradley, Vernick, Robert C, Bahekar, Amol, Patel, Divyang, Ncogo Alene, Inmaculada   +4 more
openaire   +2 more sources